Share on StockTwits
 

NuVasive (NASDAQ:NUVA) is scheduled to be posting its Q413 quarterly earnings results on Monday, March 3rd. Analysts expect NuVasive to post earnings of $0.32 per share and revenue of $181.24 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

NuVasive (NASDAQ:NUVA) opened at 37.10 on Friday. NuVasive has a one year low of $18.31 and a one year high of $38.79. The stock’s 50-day moving average is $36.49 and its 200-day moving average is $30.21. The company’s market cap is $1.655 billion.

A number of research firms have recently commented on NUVA. Analysts at Zacks upgraded shares of NuVasive from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 4th. They now have a $41.40 price target on the stock. On the ratings front, analysts at Canaccord Genuity raised their price target on shares of NuVasive from $34.00 to $51.00 in a research note on Wednesday, January 22nd. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann upgraded shares of NuVasive from a “market perform” rating to an “outperform” rating in a research note on Wednesday, January 22nd. They now have a $45.00 price target on the stock, up previously from $33.00. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $34.80.

NuVasive, Inc (NASDAQ:NUVA) is a medical device company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.